Genelux (GNLX)

• Market cap: $132M
• 1 day: -3.61%
• 5 days: -0.68%
• 1 month: -2.33%
• 3 months: 10.11%
• 6 months: 7.69%
• Year to date: -35.38%
• 1 year: -13.27%
• 5 years: -52.2%
• 10 years: -52.2%
• Sector: Healthcare
• Industry: Biotechnology

About: Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Employees: 26